As manufacturers invest in clinical development of rare disease therapies, payers are examining disease prevalence estimates and determining reimbursements. In this article published in Life Science Leader, Cécile Matthews, Bhavesh Patel, and Owen Male discuss factors payers are considering for such reimbursements. The authors recently conducted an analysis of 15 rare and ultra-rare disease therapies recently approved in France, Germany, Italy, Spain, the UK, and Japan to better understand the factors payers are now considering for reimbursement of rare disease drugs.
Click here to read the article.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...